5094-14-4

13,14-dihydro-15-keto Prostaglandin E₁ (PGE₁) is a metabolite of PGE₁ with much reduced biological activity. Steady state plasma concentrations are about 10 pg/ml. 13,14-dihydro-15-keto PGE₁ is a weak inhibitor of ADP-induced platelet aggregation in human PRP and washed platelets with IC₅₀ values of 54 and 200 μM, respectively, compared to PGE₁ which has an IC₅₀ of 40 nM.

15-Keto Prostaglandin E0 is a metabolite of Prostaglandin E1 (P838600) and has been shown to induce arterial thromboresistance in experimental animals and in man, but with several magnitudes higher concentrations than Prostaglandin E1. 15-Keto Prostaglandin E0 is also used as the active ingredient in compositions used for the treatment of external secretion disorders.

ChEBI: 13,14-dihydro-15-oxoprostaglandin E1 is a prostaglandin E obtained by formal oxidation of the 15-hydroxy group and hydrogenation of the 13,14-double bond of prostaglandin E1. It has a role as a human xenobiotic metabolite. It is functionally related to a prostaglandin E1. It is a conjugate acid of a 13,14-dihydro-15-oxoprostaglandin E1(1-).

[1] R. KATZENSCHLAGER . Synergism between PGE1-metabolites (13,14-dihydro-prostaglandin E1, 15-keto prostaglandin E1, 15-keto-13,14-dihydro-prostaglandin E1) and nitric oxide (NO) on platelet aggregation[J]. Prostaglandins, leukotrienes, and essential fatty acids, 1992, 45 3: Pages 207-210. DOI: 10.1016/0952-3278(92)90114-x